Ciltacabtagene autoleucel

Ask MedXY AI

Latest news

Tag

Hematology-OncologyCAR T-cell therapyCiltacabtagene autoleucel

Real-World Impact of Cilta-cel versus Ide-cel in CAR T-Cell Therapy for Multiple Myeloma: Insights from the German DRST Registry

By MedXY|Oct 14, 2025

A registry analysis in Germany reveals superior remission conversion and progression-free survival with ciltacabtagene autoleucel compared to idecabtagene vicleucel in heavily pretreated multiple myeloma, supporting individualized CAR T the

$Potential Curative Impact of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Five-Year Outcomes from CARTITUDE-1$

Clinical UpdatesCAR-T TherapyCiltacabtagene autoleucel

Potential Curative Impact of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Five-Year Outcomes from CARTITUDE-1

By MedXY|Oct 7, 2025

CARTITUDE-1 demonstrates that a single infusion of ciltacabtagene autoleucel (cilta-cel) yields durable ≥5-year remission and extended survival in heavily pretreated relapsed/refractory multiple myeloma, with compelling MRD negativity and a